Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at urna id nisi suscipit fringilla quis sit amet leo. Donec lobortis quis lacus eget consectetur.
Text intro statement. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus at urna id nisi suscipit fringilla quis sit amet leo. Donec lobortis quis lacus eget consectetur.
The Ihnat Lab studies how anticancer drugs differ in their ability to induce immunogenic cell death in triple-negative breast cancer, with the goal of identifying treatment strategies that improve antitumor immune responses and strengthen immunotherapy.
Our research goals are to develop a therapeutic treatment for traumatic brain injury (TBI) and novel therapies for post-traumatic stress disorder (PTSD) and pain.
The Agrahari Lab integrates a multidisciplinary approach to design innovative nanoformulations and biomaterial-based therapeutics that enable minimally invasive, localized, and targeted drug delivery for ocular and hearing disorders.
Research in my laboratory focuses on developing innovative immunotherapeutic strategies that harness the body's natural host defense mechanisms. Our work centers on investigating underlying mechanisms...
The primary focus of our lab is to develop a multi-targeted peptide drug that halts the decline in cognitive function associated with Alzheimer’s disease (AD). We focus on in vitro and in vivo preclinical testing of peptide candidates. Our goal is...
The Pereira lab develops first-in-class peptide therapeutics inspired by the neutrophil protein CAP37 to address multidrug-resistant Gram-negative infections. We focus on high-impact settings—especially ocular and...